PTX unveils new clinic-ready CAR-T enhancement platform
Filed with ASX · · 6 pages · English
Opens up an entirely new commercial platform for external collaborations and sales to other cell therapy companies, and can enhance Prescient’s own OmniCAR programs oncology company developing personalised therapies to treat cancer, today unveils its high-performance cell therapy manufacturing enhancement technology, named CellPryme-M. CellPryme-M is a platform technology that produces superior
Prescient Therapeutics Limited on 6ix
In the deck
Story so far
Earlier from Prescient Therapeutics
- PTX-200 AML expansion after another complete response
- March 2022 Quarterly Update and Appendix 4C
- Recruitment Open for Expansion Cohort of Phase 1B Study
- December 2021 Quarterly Update and Appendix 4C
- September 2021 Quarterly Activities and Appendix 4C
Later from Prescient Therapeutics
- PTX CellPryme-M presentation
- Key OmniCAR Patent Granted in US
- US FDA Grants Orphan Drug Designation to PTX-100 for PTCL
- June 2022 Quarterly Update and Appendix 4C
- PTX OmniCAR cell manufacturing contract for clinical trials
Follow Prescient Therapeutics into a list and get an email when it puts out news.
Follow Prescient Therapeutics